Description: Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Home Page: www.altoneuroscience.com
369 South San Antonio Road
Los Altos,
CA
94022
United States
Phone:
650 200 0412
Officers
| Name | Title |
|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, CEO & President |
| Mr. Nicholas C. Smith | CFO & Secretary |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer |
| Ms. Melissa Berman | Vice President of Finance & Accounting |
| Ms. Erin R. McQuade J.D. | General Counsel & Chief Administrative Officer |
| Ms. Jessica Powell | Chief Development Officer |
| Mr. Fadi Abdel M.D. | Senior Vice President of Innovation |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6258 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-02-02 |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |